Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial
Authors' conclusion
In adults with obesity, colchicine significantly affects circulating leukocyte populations involved in both innate and adaptive immune systems along with the associated inflammatory secretome.
Study context
- Population
- Adults with obesity
- Participants
- 35 adults
- Comparison
- Colchicine 0.6 mg twice daily vs placebo for 3 months
Methodological detailsdouble-blind
- Double-blind
Primary result
As reported in the abstract
Circulating leukocyte populations · 3 months
- Colchicine altered multiple innate immune cell populations (dendritic cells, lymphoid progenitor cells, monocytes, natural killer cells) vs placebo
- Colchicine reduced CD4+ T effector cells and CD8+ T cytotoxic cells
- Colchicine increased CD4+ and CD8+ T central memory cells and activated CD38High CD8+ T cells
Further findings
Associations of immune cell changes with inflammatory biomarkers
- Among all subjects and within the colchicine group, changes in natural killer cells were significantly positively associated with reductions in inflammation biomarkers (cyclooxygenase 2, pulmonary surfactant-associated protein D, myeloperoxidase, proteinase 3, interleukin-16, resistin)
- Changes in dendritic cells positively correlated with changes in serum heart-type fatty acid-binding protein
- Changes in CD4+ T effector cells associated with changes in serum heart-type fatty acid-binding protein
Original publication
Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial. Obesity (Silver Spring). Published 11 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →